Press Release

19.10.2015

A novel algorithm based on serum biomarker SCCA-IgM improves prediction of histological NASH

During the monothematic AISF meeting held in Modena on 8-10 October 2015, Xeptagen presented a poster entitled: “A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH”. The study, in collaboration with the Department of Clinical Medicine, University of Padova, shows the accuracy of a novel algorithm that analyses SCCA-IgM serological levels and other common clinical parameters in order to predict the probability of NASH in HCV-positive patients.

Keywords: NASH, Biomarker, Algorithm, SCCA-IgM, NAFLD